此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项测试 Staccato Alprazolam 在 12 岁及以上患有刻板性长期癫痫发作的研究参与者中的疗效和安全性的研究

2026年11月5日 更新者:UCB Biopharma SRL

一项双盲、随机、安慰剂对照、多中心、门诊患者、平行组研究,以评估 Staccato 阿普唑仑在 12 岁及以上患有刻板性长期癫痫发作的研究参与者中的疗效和安全性

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

研究概览

研究类型

介入性

注册 (估计的)

350

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:UCB Cares
  • 电话号码:1-844-599-2273 (USA)
  • 邮箱:UCBCares@ucb.com

学习地点

      • Beijing、中国
        • 招聘中
        • Ep0162 20246
      • Beijing、中国
        • 招聘中
        • Ep0162 20299
      • Beijing、中国
        • 撤销
        • Ep0162 20128
      • Beijing、中国
        • 完全的
        • Ep0162 20268
      • Changchun、中国
        • 招聘中
        • Ep0162 20261
      • Chengdu、中国
        • 招聘中
        • Ep0162 20133
      • Chengdu、中国
        • 招聘中
        • Ep0162 20137
      • Chongqing、中国
        • 撤销
        • Ep0162 20250
      • Chongqing、中国
        • 招聘中
        • Ep0162 20334
      • Fuzhou、中国
        • 招聘中
        • Ep0162 20179
      • Guangzhou、中国
        • 招聘中
        • Ep0162 20269
      • Guangzhou、中国
        • 招聘中
        • Ep0162 20300
      • Guangzhou、中国
        • 招聘中
        • Ep0162 20124
      • Guangzhou、中国
        • 完全的
        • Ep0162 20260
      • Guangzhou、中国
        • 完全的
        • Ep0162 20264
      • Hangzhou、中国
        • 招聘中
        • Ep0162 20022
      • Kunming、中国
        • 招聘中
        • Ep0162 20320
      • Lanzhou、中国
        • 招聘中
        • Ep0162 20258
      • Nanchang、中国
        • 撤销
        • Ep0162 20253
      • Nanjing、中国
        • 招聘中
        • Ep0162 20267
      • Nanning、中国
        • 招聘中
        • Ep0162 20331
      • Qingdao、中国
        • 招聘中
        • Ep0162 20333
      • Shanghai、中国
        • 撤销
        • Ep0162 20123
      • Shanghai、中国
        • 招聘中
        • Ep0162 20292
      • Shenzhen、中国
        • 撤销
        • Ep0162 20332
      • Shijiazhuang、中国
        • 招聘中
        • Ep0162 20289
      • Suzhou、中国
        • 招聘中
        • Ep0162 20119
      • Tianjin、中国
        • 招聘中
        • Ep0162 20257
      • Wenzhou、中国
        • 招聘中
        • Ep0162 20025
      • Wuhan、中国
        • 撤销
        • Ep0162 20252
      • Yinchuan、中国
        • 撤销
        • Ep0162 20255
      • Zhanjiang、中国
        • 招聘中
        • Ep0162 20262
      • Zhengzhou、中国
        • 招聘中
        • Ep0162 20251
      • Blagoevgrad、保加利亚
        • 招聘中
        • Ep0162 40650
      • Pazardzhik、保加利亚
        • 招聘中
        • Ep0162 40708
      • Pleven、保加利亚
        • 完全的
        • Ep0162 40665
      • Pleven、保加利亚
        • 完全的
        • Ep0162 40709
      • Sofia、保加利亚
        • 完全的
        • Ep0162 40651
      • Balassagyarmat、匈牙利
        • 招聘中
        • Ep0162 40666
      • Budapest、匈牙利
        • 招聘中
        • Ep0162 40673
      • Budapest、匈牙利
        • 招聘中
        • Ep0162 40704
      • Debrecen、匈牙利
        • 招聘中
        • Ep0162 40653
      • Aachen、德国
        • 撤销
        • Ep0162 40577
      • Berlin、德国
        • 招聘中
        • Ep0162 40683
      • Bielefeld、德国
        • 招聘中
        • Ep0162 40685
      • Erlangen、德国
        • 招聘中
        • Ep0162 40023
      • Frankfurt am Main、德国
        • 招聘中
        • Ep0162 40645
      • Kehl-kork、德国
        • 完全的
        • Ep0162 40689
      • Marburg、德国
        • 招聘中
        • Ep0162 40529
      • München、德国
        • 撤销
        • Ep0162 40724
      • Catanzaro、意大利
        • 撤销
        • Ep0162 40690
      • Genova、意大利
        • 招聘中
        • Ep0162 40674
      • Milan、意大利
        • 招聘中
        • Ep0162 40144
      • Pavia、意大利
        • 招聘中
        • Ep0162 40477
      • Roma、意大利
        • 招聘中
        • Ep0162 40257
      • Roma、意大利
        • 完全的
        • Ep0162 40675
      • Brno、捷克语
        • 招聘中
        • Ep0162 40670
      • Ostrava - Poruba、捷克语
        • 招聘中
        • Ep0162 40672
      • Prague、捷克语
        • 招聘中
        • Ep0162 40671
      • Prague、捷克语
        • 招聘中
        • Ep0162 40714
      • Prague、捷克语
        • 完全的
        • Ep0162 40063
      • Fukuoka、日本
        • 招聘中
        • Ep0162 20248
      • Hachioji-shi、日本
        • 招聘中
        • Ep0162 20070
      • Hamamatsu、日本
        • 撤销
        • Ep0162 20237
      • Hiroshima、日本
        • 招聘中
        • Ep0162 20249
      • Hōfu、日本
        • 招聘中
        • Ep0162 20236
      • Itami、日本
        • 招聘中
        • Ep0162 20239
      • Kodaira、日本
        • 招聘中
        • Ep0162 20143
      • Koshi-shi、日本
        • 招聘中
        • Ep0162 20315
      • Kyoto、日本
        • 招聘中
        • Ep0162 20147
      • Nagakute、日本
        • 完全的
        • Ep0162 20243
      • Nagoya、日本
        • 招聘中
        • Ep0162 20235
      • Niigata、日本
        • 招聘中
        • Ep0162 20238
      • Osaka、日本
        • 招聘中
        • Ep0162 20302
      • Sapporo、日本
        • 招聘中
        • Ep0162 20316
      • Shimotsuga-gun、日本
        • 招聘中
        • Ep0162 20337
      • Shinjuku-ku、日本
        • 招聘中
        • Ep0162 20297
      • Shizuoka、日本
        • 招聘中
        • Ep0162 20240
      • Suita、日本
        • 招聘中
        • Ep0162 20242
      • Tōon、日本
        • 招聘中
        • Ep0162 20266
      • Yamagata、日本
        • 招聘中
        • Ep0162 20244
      • Ōmura、日本
        • 招聘中
        • Ep0162 20241
      • Bron、法国
        • 招聘中
        • Ep0162 40681
      • Bron、法国
        • 撤销
        • Ep0162 40688
      • Dijon、法国
        • 撤销
        • Ep0162 40680
      • Marseille、法国
        • 撤销
        • Ep0162 40130
      • Paris、法国
        • 招聘中
        • Ep0162 40682
      • Paris、法国
        • 撤销
        • Ep0162 40019
      • Rennes、法国
        • 招聘中
        • Ep0162 40201
      • Strasbourg、法国
        • 招聘中
        • Ep0162 40199
      • Bydgoszcz、波兰
        • 招聘中
        • Ep0162 40707
      • Gdansk、波兰
        • 招聘中
        • Ep0162 40677
      • Krakow、波兰
        • 撤销
        • Ep0162 40219
      • Krakow、波兰
        • 招聘中
        • Ep0162 40842
      • Krakow、波兰
        • 完全的
        • Ep0162 40502
      • Lublin、波兰
        • 完全的
        • Ep0162 40676
      • Nowa Sól、波兰
        • 招聘中
        • Ep0162 40091
      • Poznan、波兰
        • 撤销
        • Ep0162 40153
      • Świdnik、波兰
        • 完全的
        • Ep0162 40678
      • Fitzroy、澳大利亚
        • 招聘中
        • Ep0162 30016
      • Herston、澳大利亚
        • 招聘中
        • Ep0162 30030
      • Melbourne、澳大利亚
        • 撤销
        • Ep0162 30027
      • South Brisbane、澳大利亚
        • 主动,不招人
        • Ep0162 30031
    • Arizona
      • Phoenix、Arizona、美国、85004
        • 招聘中
        • Ep0162 50506
      • Scottsdale、Arizona、美国、85253
        • 招聘中
        • Ep0162 50720
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • 完全的
        • Ep0162 50494
    • California
      • Downey、California、美国、90242
        • 招聘中
        • Ep0162 50118
      • La Jolla、California、美国、92037
        • 招聘中
        • Ep0162 50416
      • Long Beach、California、美国、90806
        • 招聘中
        • Ep0162 50702
      • Los Angeles、California、美国、90095
        • 撤销
        • Ep0162 50505
      • Orange、California、美国、92868
        • 完全的
        • Ep0162 50492
      • Poway、California、美国、92064
        • 撤销
        • Ep0162 50722
      • Sacramento、California、美国、95817
        • 招聘中
        • Ep0162 50716
    • Connecticut
      • New Haven、Connecticut、美国、06519
        • 完全的
        • Ep0162 50367
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20037
        • 招聘中
        • Ep0162 50088
    • Florida
      • Boca Raton、Florida、美国、33486
        • 撤销
        • Ep0162 50721
      • Gulf Breeze、Florida、美国、32561
        • 完全的
        • Ep0162 50515
      • Jacksonville、Florida、美国、32224-1865
        • 招聘中
        • Ep0162 50342
      • Jacksonville、Florida、美国、32209-6533
        • 招聘中
        • Ep0162 50508
      • Miami、Florida、美国、33136
        • 招聘中
        • Ep0162 50199
      • Miami、Florida、美国、33176
        • 招聘中
        • Ep0162 50676
      • Orlando、Florida、美国、32806
        • 完全的
        • Ep0162 50509
      • Rockledge、Florida、美国、32955
        • 招聘中
        • Ep0162 50703
      • Tampa、Florida、美国、33606
        • 招聘中
        • Ep0162 50308
    • Hawaii
      • Honolulu、Hawaii、美国、96817
        • 招聘中
        • Ep0162 50323
    • Idaho
      • Boise、Idaho、美国、83702
        • 招聘中
        • Ep0162 50512
    • Illinois
      • Chicago、Illinois、美国、60611
        • 招聘中
        • Ep0162 50493
      • Springfield、Illinois、美国、62702
        • 撤销
        • Ep0162 50375
    • Indiana
      • Fort Wayne、Indiana、美国、46804
        • 招聘中
        • Ep0162 50504
    • Kentucky
      • Lexington、Kentucky、美国、40536
        • 撤销
        • Ep0162 50561
    • Louisiana
      • New Orleans、Louisiana、美国、70122
        • 招聘中
        • Ep0162 50517
      • New Orleans、Louisiana、美国、70121
        • 撤销
        • Ep0162 50395
    • Maryland
      • Baltimore、Maryland、美国、21287
        • 撤销
        • Ep0162 50093
      • Bethesda、Maryland、美国、20817
        • 撤销
        • Ep0162 50488
    • Massachusetts
      • Boston、Massachusetts、美国、02118
        • 招聘中
        • Ep0162 50615
      • Boston、Massachusetts、美国、02215
        • 完全的
        • Ep0162 50047
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 完全的
        • Ep0162 50110
    • Missouri
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Ep0162 50507
    • Nevada
      • Las Vegas、Nevada、美国、89128
        • 撤销
        • Ep0162 50499
    • New Jersey
      • Neptune City、New Jersey、美国、07753
        • 撤销
        • Ep0162 50626
      • New Brunswick、New Jersey、美国、08901
        • 招聘中
        • Ep0162 50299
    • New York
      • Buffalo、New York、美国、14221
        • 招聘中
        • Ep0162 50497
      • New Hyde Park、New York、美国、11042
        • 完全的
        • Ep0162 50625
      • New York、New York、美国、10016
        • 招聘中
        • Ep0162 50298
      • New York、New York、美国、10029
        • 招聘中
        • Ep0162 50490
      • New York、New York、美国、10075
        • 招聘中
        • Ep0162 50518
      • Rochester、New York、美国、14642
        • 招聘中
        • Ep0162 50034
    • North Carolina
      • Charlotte、North Carolina、美国、28204
        • 招聘中
        • Ep0162 50514
      • Charlotte、North Carolina、美国、28207
        • 撤销
        • Ep0162 50487
      • Durham、North Carolina、美国、27705
        • 招聘中
        • Ep0162 50715
    • Ohio
      • Akron、Ohio、美国、44308
        • 撤销
        • Ep0162 50371
      • Cleveland、Ohio、美国、44195
        • 撤销
        • Ep0162 50528
    • Oregon
      • Portland、Oregon、美国、97239-3098
        • 撤销
        • Ep0162 50510
      • Portland、Oregon、美国、97227
        • 完全的
        • Ep0162 50724
      • Portland、Oregon、美国、97239
        • 招聘中
        • Ep0162 50701
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Ep0162 50096
      • Philadelphia、Pennsylvania、美国、19107
        • 招聘中
        • Ep0162 50364
      • Philadelphia、Pennsylvania、美国、19140
        • 招聘中
        • Ep0162 50089
      • Pittsburgh、Pennsylvania、美国、15212
        • 招聘中
        • Ep0162 50511
      • Pittsburgh、Pennsylvania、美国、15213
        • 招聘中
        • Ep0162 50491
    • Tennessee
      • Chattanooga、Tennessee、美国、37403
        • 招聘中
        • Ep0162 50700
      • Memphis、Tennessee、美国、38103-2800
        • 招聘中
        • Ep0162 50513
      • Nashville、Tennessee、美国、37232
        • 招聘中
        • Ep0162 50103
    • Texas
      • Austin、Texas、美国、78749
        • 招聘中
        • Ep0162 50731
      • Houston、Texas、美国、77459
        • 招聘中
        • Ep0162 50525
      • Houston、Texas、美国、77030
        • 招聘中
        • Ep0162 50714
      • Round Rock、Texas、美国、78681
        • 撤销
        • Ep0162 50496
    • Utah
      • Salt Lake City、Utah、美国、84132
        • 招聘中
        • Ep0162 50473
    • Virginia
      • Winchester、Virginia、美国、22601
        • 招聘中
        • Ep0162 50726
      • Birmingham、英国
        • 招聘中
        • Ep0162 40686
      • Cardiff、英国
        • 撤销
        • Ep0162 40300
      • Glasgow、英国
        • 招聘中
        • Ep0162 40735
      • London、英国
        • 招聘中
        • Ep0162 40833
      • Oxford、英国
        • 招聘中
        • Ep0162 40163
      • Salford、英国
        • 招聘中
        • Ep0162 40108
      • Barcelona、西班牙
        • 招聘中
        • Ep0162 40160
      • L'Hospitalet de Llobregat、西班牙
        • 招聘中
        • Ep0162 40157
      • Madrid、西班牙
        • 招聘中
        • Ep0162 40540
      • Pamplona、西班牙
        • 招聘中
        • Ep0162 40352
      • Seville、西班牙
        • 招聘中
        • Ep0162 40668
      • Terrassa、西班牙
        • 招聘中
        • Ep0162 40453
      • Valencia、西班牙
        • 招聘中
        • Ep0162 40230
      • Valladolid、西班牙
        • 完全的
        • Ep0162 40667

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participant must be ≥12 years of age at the Baseline/Randomization Visit

  • Participant must have a study caregiver ≥18 years of age at the Screening Visit; the study caregiver(s) must be a relative, partner, friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures

  • Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:

    1. Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
    2. Episodes of a focal seizure with a minimum duration of 3 minutes
    3. Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
  • Prior to the Screening Visit, participant has experienced ≥4 stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have occurred within the 3 months prior to the Screening Visit

  • Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of epilepsy and within the 5 years prior to the Screening Visit, that confirms the absence of a progressive neurological disorder

  • Participant is receiving a regimen of antiseizure medications (ASMs) that has been stable (ie, no addition or removal of ASM[s]; dose adjustments are permitted to ASM[s]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to the Screening Visit

  • Male and female participants:

    1. A male participant must agree to use contraception during the Outpatient Treatment Period and for at least 7 days after IMP administration and refrain from donating sperm during this period
    2. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the Outpatient Treatment Period and for at least 30 days after IMP administration

  • Participant is capable of giving signed informed consent (or giving assent, where required), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The ICF or a specific assent form, where required, will be signed and dated by minors

  • The participant's study caregiver(s) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the iPMP

Exclusion Criteria:

  • Participant has a current history of alcohol or drug use disorder, as defined in the Diagnostic and Statistical Manual of Mental Disorders 5, within the previous 1 year
  • Participant has a known hypersensitivity to any components of the IMP or comparable drugs (and/or an investigational device) as stated in this protocol or to albuterol (or similar bronchospasm rescue medication if needed to meet country-specific requirements)
  • Participant has a diagnosis of atrial fibrillation or mitral stenosis
  • Participant has a history of convulsive (generalized tonic-clonic) status epilepticus in the 8 weeks prior to the Screening Visit
  • Participant has a history or presence of known nonepileptic seizures which cannot be distinguished from qualifying epileptic seizures
  • Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food) and/or acute respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation)
  • Participant has a clinically significant chronic pulmonary disorder other than mild asthma (eg, chronic obstructive pulmonary disease, restrictive lung diseases [including idiopathic pulmonary fibrosis]) and/or recent history or presence of hemoptysis or pneumothorax
  • Participant has had a positive antigen test for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced moderate to severe signs/symptoms of respiratory distress necessitating hospitalization or outpatient treatment such as ambulatory oxygen, extensive treatment with inhaler medications, and/or oral medications for a duration of 4 weeks or more, unless full resolution occurred at least 6 months prior to Screening
  • Participant has experienced a upper respiratory tract infection within 4 weeks or bronchitis/pneumonia within 3 months before the Screening Visit
  • Participant has a history or presence of acute narrow-angle glaucoma
  • Participant has a condition for which oral alprazolam is contraindicated (eg, myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome)
  • Participant has a history or presence of long QT syndrome, a family history of sudden death due to long QT syndrome, or unexplained syncope
  • Chronic use of benzodiazepines for more than 3 days within a period of 7 days will be allowed for approximately 30 % of study participants
  • Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone
  • Participant is taking any opioids (eg, fentanyl, oxycodone, morphine) or sedative hypnotics on a chronic basis
  • Participant is taking nonselective beta blockers on a chronic basis
  • Participant is taking pharmacotherapy for an active major psychiatric disorder where major changes in regimen are needed or anticipated during the study
  • Participant has been treated with vagal nerve stimulation (VNS) for less than 6 months or VNS settings have changed within 30 days before the Screening Visit
  • Participant has a clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
  • Participant has an oxygen saturation <95 % (or less than normal in regions of altitude >2500 meters) for greater than 30 seconds during the Screening Visit. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
  • Participant has >2.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome or >2.0xULN total bilirubin for liver impairment)
  • Participant has current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis
  • Participant has a QT interval corrected for heart rate (QTc) >450 msec (males), QTc interval >470 msec (females), or QTc interval >480 msec (participants with bundle branch block), PR interval ≥220 msec, or any other clinically significant electrocardiogram (ECG) abnormality according to the Investigator i) The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF). It is either machine-read or manually over-read
  • Participant has a positive urine screen for drugs of abuse at the Screening Visit
  • Participant has a blood pressure (BP) or heart rate (HR) outside the following range after 5 minutes rest: systolic BP: 90 mmHg to 150 mmHg; diastolic BP: 4 0mmHg to 95 mmHg; HR: 50 bpm to 100 bpm. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Staccato alprazolam Arm

Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.

Route of administration: Inhalation

Participants will receive one dose of Staccato alprazolam during the Treatment Period.

其他名称:
  • UCB7538
安慰剂比较:Placebo Arm

Participants randomized to this arm will receive a single dose of placebo by inhalation.

Route of administration: Inhalation

Participants will receive one dose of placebo during the Treatment Period.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administration
大体时间:From start of IMP treatment through 6 hours

Treatment success for the treated seizure is defined as termination of the seizure within 90 seconds after IMP administration.

From start of IMP treatment through 6 hours
Treatment success for the treated seizure with no recurrence up to 2 hours
大体时间:From start of IMP treatment through 2 hours

Treatment success for the treated seizure is defined as termination of the treated seizure within 90 seconds after IMP administration and no recurrence of seizure(s) from IMP administration to 2 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 2 hours after IMP administration.

From start of IMP treatment through 2 hours

次要结果测量

结果测量
措施说明
大体时间
Treatment success for treated seizure with no recurrence after 4 hours
大体时间:From start of IMP treatment through 4 hours

Treatment success defined as termination of the treated seizure within 90 seconds after IMP administration, with no recurrence of seizure(s) up to 4 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 4 hours after IMP administration.

From start of IMP treatment through 4 hours
Treatment success for treated seizure with no recurrence after 6 hours
大体时间:From start of IMP treatment through 6 hours

Treatment success defined as termination of the treated seizure within 90 seconds after IMP administration, with no recurrence of seizure(s) up to 6 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 6 hours after IMP administration.

From start of IMP treatment through 6 hours
Time from IMP administration to cessation of the treated seizure
大体时间:From start of IMP treatment through 6 hours

The time will be assessed from IMP administration to cessation of the treated seizure (taking administration of seizure rescue treatment as censoring point).

From start of IMP treatment through 6 hours
Frequency of respiratory treatment emergent adverse events (TEAEs)
大体时间:From start of IMP treatment up to the Safety Follow-up Visit (Week 19)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP.

From start of IMP treatment up to the Safety Follow-up Visit (Week 19)
Number of subsequent seizure(s) up to 2 hours after IMP administration
大体时间:From start of IMP treatment through 2 hours

The number of subsequent seizure(s) will be assessed up to 2 hours after IMP administration.

From start of IMP treatment through 2 hours
Time to first subsequent seizure up to 2 hours after IMP administration
大体时间:From start of IMP treatment through 2 hours

The time to first subsequent seizure will be assessed up to 2 hours after IMP administration and is defined as time from end of IMP treated seizure to start of first subsequent seizure.

From start of IMP treatment through 2 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:UCB Cares、001 844 599 2273 (UCB)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年12月7日

初级完成 (估计的)

2027年3月29日

研究完成 (估计的)

2027年3月29日

研究注册日期

首次提交

2021年9月30日

首先提交符合 QC 标准的

2021年9月30日

首次发布 (实际的)

2021年10月14日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • EP0162
  • 2021-002686-18 (EudraCT编号)
  • U1111-1303-2588 (其他标识符:Universal Trial Number (UTN))
  • 2024-510950-29 (注册表标识符:EU CT Number)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of reidentifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

IPD 共享时间框架

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

IPD 共享访问标准

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅